...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Re: ZEN-3694 Single Agent Trial Status

Fun speculation.

My POV is that neither company has an approved drug. Also, I sense that BPs are very concervative. So my perspective is that one or more BPs may be interested but at what price at this stage. Don has fought hard for many years and he fully understands the potential held in both companies. He will not let that slip away at a low price. Nor will Eastern let that happen. Also, at this stage it would be difficult to put a value on each company, none the less the combined companies. I am sure that the BPs understand the market value of the 2 test drugs. Applying a probability of success fo each drug and applying some cost and pricing scenarios would provide a reference system. Plus, there is the value of the IP.

I speculate we are not yet at a buyout stage but i do believe there is some sort of Hepa deal being worked out. The challenge is that it needs to be a $120,000,000 plus deal.

Just some thoughts.

GLTA

Toinv

6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM
Share
New Message
Please login to post a reply